{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-162652","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2024-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.705509+00:00","generated_at":"2026-06-01T04:05:30.965861+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CytomX Therapeutics appoints Chris Ogden as CFO effective June 15, 2024","bullets":["Chris Ogden promoted from SVP Finance & Accounting to CFO, effective June 15, 2024.","Ogden continues as Principal Accounting and Financial Officer, roles held since September 2022.","Granted option to purchase 75,000 shares and RSU award for 17,500 shares under 2015 Equity Incentive Plan.","No family relationships or arrangements with other parties in connection with his appointment."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-162652","json":"https://secwatch.observer/filing/0001193125-24-162652.json","markdown":"https://secwatch.observer/filing/0001193125-24-162652.md","text":"https://secwatch.observer/filing/0001193125-24-162652.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524162652/0001193125-24-162652-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524162652/d831468d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:05:30.965861+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f0f3699dbb","claim":"Chris Ogden was appointed as Chief Financial Officer at CytomX Therapeutics, Inc..","evidence_excerpt":"On June 12, 2024, CytomX Therapeutics, Inc. (the “Company”) appointed Chris Ogden to serve as the Company’s Chief Financial Officer effective June 15, 2024 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312524162652/0001193125-24-162652-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}